{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:03:24Z","timestamp":1790946204667,"version":"4.1.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Wild-type epidermal growth factor receptor (EGFRwt) is commonly implicated in tumor growth, yet most of the approved EGFR-targeted therapies are against mutant receptor isoforms, and patients with EGFRwt-dependent cancers have limited treatment options. We herein explored the potential to inhibit EGFRwt with five top screened hits retrieved from Food and Drug Administration (FDA)-approved kinase inhibitors library, originally developed for MET-overexpressing cancers for potential drug repurposing approach. Induced-fit docking showed that all five molecules bound the ATP-binding pocket of EGFRwt, with compound D4 emerging as the top candidate due to key interactions with ASP855 (DFG motif) and MET793 (hinge region), underscoring its favorable engagement. To further assess this interaction, we then conducted 100 ns molecular dynamics (MD) simulations, confirming the structural stability of the EGFRwt\u2013D4 complex, with stable root-mean-square deviation (RMSD) values and maintained secondary structure elements. Free energy of binding calculations using the Molecular Mechanics\/Poisson\u2013Boltzmann Surface Area (MM\/PBSA) method supported these findings, with D4 showing the most favourable interaction, dominated by Van Der Waals and electrostatic contributions from key catalytic amino acid. Our research, with further experimental validation, could be helpful to support that certain MET inhibitors, especially D4, are promising competitive inhibitors of EGFRwt, offering potential for the development of new therapeutic strategies targeting EGFRwt-driven cancers.<\/jats:p>","DOI":"10.1371\/journal.pone.0350847","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:24:27Z","timestamp":1782149067000},"page":"e0350847","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identifying potential inhibitors for wild-type EGFR tyrosine kinase through a cross-talk pathway strategy and an in-silico drug repurposing method"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-4405","authenticated-orcid":true,"given":"Dorra","family":"Abdelmalek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawther","family":"Bedchich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahmi","family":"Smaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Kraiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ali","family":"Mosrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Sami","family":"Aifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"48","key":"pone.0350847.ref001","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"7","author":"Y-L Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"pone.0350847.ref002","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"A Midha","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"24","key":"pone.0350847.ref003","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2010.33.3757","article-title":"Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer","volume":"29","author":"Q Zhou","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0350847.ref004","first-page":"65","article-title":"Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study","volume":"3","author":"N Bi","year":"2022","journal-title":"J Natl Cancer Cent"},{"issue":"3","key":"pone.0350847.ref005","doi-asserted-by":"crossref","first-page":"1800986","DOI":"10.1183\/13993003.00986-2018","article-title":"Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning","volume":"53","author":"S Wang","year":"2019","journal-title":"Eur Respir J"},{"issue":"10","key":"pone.0350847.ref006","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"TS Mok","year":"2009","journal-title":"N Engl J Med"},{"issue":"18","key":"pone.0350847.ref007","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"PA J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0350847.ref008","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy","volume":"107","author":"Y Kobayashi","year":"2016","journal-title":"Cancer Sci"},{"issue":"7","key":"pone.0350847.ref009","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"MA Lemmon","year":"2010","journal-title":"Cell"},{"issue":"5","key":"pone.0350847.ref010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"P Wee","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"8","key":"pone.0350847.ref011","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Y Yarden","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"pone.0350847.ref012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"S Sigismund","year":"2018","journal-title":"Mol Oncol"},{"issue":"2","key":"pone.0350847.ref013","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"J-C Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0350847.ref014","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","volume":"3","author":"J Greenhalgh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"pone.0350847.ref015","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.oraloncology.2012.06.016","article-title":"Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature","volume":"48","author":"G Rabinowits","year":"2012","journal-title":"Oral Oncol"},{"key":"pone.0350847.ref016","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"PT Harrison","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"pone.0350847.ref017","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: Rationale and progress","volume":"12","author":"E Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"pone.0350847.ref018","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy","volume":"18","author":"PM Comoglio","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"pone.0350847.ref019","first-page":"6419","article-title":"MET receptor sequence variants and amplification in lung cancer: A potential target for kinase inhibitors","volume":"62","author":"G Maulik","year":"2002","journal-title":"Cancer Research"},{"issue":"5827","key":"pone.0350847.ref020","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"JA Engelman","year":"2007","journal-title":"Science"},{"issue":"7408","key":"pone.0350847.ref021","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"TR Wilson","year":"2012","journal-title":"Nature"},{"issue":"23","key":"pone.0350847.ref022","first-page":"11418","article-title":"HER2 and MET crosstalk in breast cancer","volume":"67","author":"YW Zhang","year":"2007","journal-title":"Cancer Research"},{"issue":"31","key":"pone.0350847.ref023","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","article-title":"Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer","volume":"24","author":"FR Hirsch","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"pone.0350847.ref024","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3390\/cancers15112998","article-title":"The Role of MET in Resistance to EGFR Inhibition in NSCLC: A review of mechanisms and treatment implications","volume":"15","author":"SL Feldt","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"pone.0350847.ref025","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14-Mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"J Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0350847.ref026","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study","volume":"13","author":"DR Camidge","year":"2012","journal-title":"Lancet Oncol"},{"issue":"19","key":"pone.0350847.ref027","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"TK Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0350847.ref028","doi-asserted-by":"crossref","first-page":"816896","DOI":"10.3389\/fphar.2021.816896","article-title":"Editorial: Clinical Therapeutic Development Against Cancers Resistant to Targeted Therapies","volume":"12","author":"F Zhou","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"pone.0350847.ref029","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s43440-023-00501-4","article-title":"Polypharmacology: Promises and new drugs in 2022","volume":"75","author":"P Ryszkiewicz","year":"2023","journal-title":"Pharmacol Rep"},{"key":"pone.0350847.ref030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/B978-0-12-822312-3.00009-6","article-title":"Chapter 16 - Design and discovery of kinase inhibitors using docking studies","volume-title":"Molecular docking for computer-aided drug design","author":"T Djikic","year":"2021"},{"issue":"9","key":"pone.0350847.ref031","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1021\/acs.jmedchem.5b01684","article-title":"Role of molecular dynamics and related methods in drug discovery","volume":"59","author":"M De Vivo","year":"2016","journal-title":"J Med Chem"},{"issue":"6","key":"pone.0350847.ref032","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"SA Hollingsworth","year":"2018","journal-title":"Neuron"},{"issue":"6","key":"pone.0350847.ref033","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/ct700119m","article-title":"Clustering molecular dynamics trajectories: 1. Characterizing the performance of different clustering algorithms","volume":"3","author":"J Shao","year":"2007","journal-title":"J Chem Theory Comput"},{"issue":"10","key":"pone.0350847.ref034","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: A promising tool to accelerate the drug discovery process","volume":"24","author":"V Parvathaneni","year":"2019","journal-title":"Drug Discov Today"},{"issue":"11","key":"pone.0350847.ref035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"MM Attwood","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"pone.0350847.ref036","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3390\/ijms21093157","article-title":"Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: A focus on transporters and lysosomal sequestration","volume":"21","author":"M Krchniakova","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"75","key":"pone.0350847.ref037","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"LV Sequist","year":"2011","journal-title":"Sci Transl Med"},{"issue":"5827","key":"pone.0350847.ref038","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"JA Engelman","year":"2007","journal-title":"Science"},{"issue":"11","key":"pone.0350847.ref039","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3390\/ijms18112420","article-title":"Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms","volume":"18","author":"T Yamaoka","year":"2017","journal-title":"Int J Mol Sci"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:24:34Z","timestamp":1782149074000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350847"}},"subtitle":[],"editor":[{"given":"Wagdy M.","family":"Eldehna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0350847","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}